Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Linkoeping University University of Gondar Armauer Hansen Research Institute, Ethiopia |
---|---|
Information provided by: | Linkoeping University |
ClinicalTrials.gov Identifier: | NCT00857116 |
The purpose of this study is to investigate whether treatment against intestinal helminths in patients with smear positive tuberculosis undergoing chemotherapy could improve the clinical outcome by enhancing host immunity.
Condition | Intervention |
---|---|
Tuberculosis |
Drug: Albendazole Drug: Placebo |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | The Impact of Deworming on Host Immunity and Clinical Outcome in Patients With Smear Positive Tuberculosis |
Estimated Enrollment: | 400 |
Study Start Date: | March 2009 |
Estimated Study Completion Date: | March 2012 |
Estimated Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Albendazole: Active Comparator
Albendazole 400mg per os once daily for three consecutive days
|
Drug: Albendazole
Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
|
Placebo: Placebo Comparator
Placebo 400mg per os for three consecutive days
|
Drug: Placebo
Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
|
Mycobacterium tuberculosis causing tuberculosis (TB) is a major global public health problem. Because of increasing multi drug resistance and the long treatment period of at least six months, new therapeutic options are urgently needed. In countries like Ethiopia where TB is endemic, chronic worm infection is also highly prevalent. Recent data support that helminth infection might limit the host response against TB by inhibition of the TH1-response that is crucial in controlling the disease. In this study we want to test the hypothesis that Albendazole treatment of patients coinfected with helminths and TB could improve clinical outcome in addition to chemotherapy against TB. Additionally we will investigate the immunological interactions between TB and chronic helminths infection.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ebba Abate, MSc | +251 911464024 | ebbaabate@yahoo.com |
Contact: Endalkachew Melese, MD | +251 911406681 | hildanaus@yahoo.com |
Ethiopia, Gondar | |
University of Gondar | Recruiting |
Gondar, Region 3, Ethiopia, Gondar, Ethiopia | |
Contact: Ebba Abate, MSc +251911464024 ebbaabate@yahoo.com | |
Contact: Endalkachew Melese, MD +251911406681 hildanaus@yahoo.com | |
Principal Investigator: Ebba Abate, MSc | |
Principal Investigator: Endalkachew Melese, MD | |
Sub-Investigator: Shitaye Alemu, MD | |
Sub-Investigator: Assefa Getachew, MD | |
Sub-Investigator: Abraham Assefa, MD PhD | |
Sub-Investigator: Alermayeho Wurku, PhD | |
Sub-Investigator: Thomas Schoen, MD PhD | |
Sub-Investigator: Olle Stendahl, Professor | |
Sub-Investigator: Jonna Idh, MD | |
Sub-Investigator: Daniel Elias, PhD |
Principal Investigator: | Ebba Abate, MSc | University of Gondar and Linkoeping University |
Principal Investigator: | Endalkachew Melese, MD | University of Gondar |
Study Director: | Thomas Schoen, MD PhD | Linkoeping University, Sweden |
Responsible Party: | University of Gondar, Ethiopia and Linkoeping University, Sweden. ( Ebba Abate ) |
Study ID Numbers: | ALBP, HLF-20060245 |
Study First Received: | March 5, 2009 |
Last Updated: | June 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00857116 History of Changes |
Health Authority: | Ethiopia: Ethical Review Committee; Sweden: Regional Ethical Review Board |
Deworming Tuberculosis TB-score Albendazole Helminths |
Albendazole Bacterial Infections Anti-Infective Agents Gram-Positive Bacterial Infections Tubulin Modulators |
Mycobacterium Infections Anthelmintics Tuberculosis Antimitotic Agents Helminthiasis |
Bacterial Infections Anti-Infective Agents Antiprotozoal Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antiplatyhelmintic Agents Mitosis Modulators Anthelmintics Antimitotic Agents Actinomycetales Infections |
Pharmacologic Actions Anticestodal Agents Albendazole Gram-Positive Bacterial Infections Antiparasitic Agents Therapeutic Uses Tubulin Modulators Mycobacterium Infections Tuberculosis |